Investing by design

Why Sanofi-Genzyme BioVentures backed immunotherapy play Immune Design

Sanofi-Genzyme BioVentures hopes last week's investment in the $32.5 million first close of immunotherapy play Immune Design Corp.'s planned $49 million series C round will advance the fund's goal of filling parent Sanofi's pipeline.

Existing investor The Column Group and new investor Topspin Partners led the round. Existing investors Alta Partners, Versant Ventures,

Read the full 526 word article

How to gain access

Continue reading with a
two-week free trial.